ACAndrew J. Cole

Andrew J. Cole

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew J. Cole has a total of 467 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy

    by Dawn Eliashiv, Vikram R. Rao, Barbara C. Jobst, Jerzy P. Szaflarski, John D. Rolston, Lesley C. Kaye, Taneeta Mindy Ganguly, Katie Bullinger, Patricia C. Dugan, David E. Burdette, et al.

    Background and ObjectivesNeuromodulation therapies are approved for the treatment of focal epilepsy based on data from randomized controlled trials (RCTs). After approval of a responsive direct bra...


  • Open Access

    Imaging in Epilepsy: Current Clinical Practice and Future Directions

    by Peter N. Hadar, Andrew J. Cole

    Neuroimaging is an essential part of epilepsy diagnosis and management. In this review, we examine the shift in our understanding of epilepsy from a focal, lesional-centric process to a broader, network-based disorder and how it has affected the acquisition and interpretation of neuroimaging for epilepsy diagnosis and management. We discuss the current clinical practice of neuroimaging in epilepsy, both in terms of acquisitions and interpretation, through computed tomography, magnetic resonance imaging (including structural, diffusion, functional, and high-field), magnetoencephalography, and nuclear and metabolic imaging. Additionally, we look ahead to some of the latest research advances in both the acquisition and analysis of these different neuroimaging modalities to help promote the eventual goal of a consolidated, multi-modality imaging approach to understanding, diagnosing, and treating epilepsy.

  • Open Access

    Harvard Electroencephalography Database: A comprehensive clinical electroencephalographic resource from four Boston hospitals

    by Chenxi Sun, Jin Jing, Niels Turley, Callison Alcott, Wan‐Yee Kang, Andrew J. Cole, Daniel M. Goldenholz, Alice Lam, Edilberto Amorim, Catherine Chu, et al.

    Objective: This article presents the Harvard Electroencephalography Database (HEEDB), a large‐scale, deidentified, and standardized electroencephalographic (EEG) resource supporting artificial intelligence‐driven and reproducible research in epilepsy and broader clinical neuroscience.Methods: HEEDB aggregates more than 280 000 EEG recordings from more than 108 000 patients across four Harvard‐affiliated hospitals. Data are harmonized using the Brain Imaging Data Structure and hosted on the Brain Data Science Platform. EEG data are linked with clinical notes, International Classification of Diseases, 10th Revision codes, medications, and EEG reports. Deidentification follows Health Insurance Portability and Accountability Act Safe Harbor standards.Results: The database includes routine, epilepsy monitoring unit, and intensive care unit EEGs across all age groups, with 73% linked to deidentified clinical reports and 96% of those matched to recordings. Findings are extracted using expert curation, regular expressions, and medical natural language processing models. Auxiliary data include diagnoses, medications, and hospital course, supporting multimodal analysis.Significance: HEEDB fills a critical gap in EEG data availability for epilepsy research. By enabling large‐scale, privacy‐compliant, and clinically relevant analysis, it accelerates the development of diagnostic tools, improves training datasets for machine learning, and promotes data‐sharing in alignment with FAIR (Findable, Accessible, Interoperable, Reusable) and National Institutes of Health data policies.


  • WONOEP appraisal: Modeling early onset epilepsies

    by Ann‐Sofie De Meulemeester, Christopher Reid, Stéphane Auvin, Peter L. Carlen, Andrew J. Cole, Roza Szlendak, Rossella Di Sapia, Solomon L. Moshé, Raman Sankar, Terence J. O'BRien, et al.

    Epilepsy has a peak incidence during the neonatal to early childhood period. These early onset epilepsies may be severe conditions frequently associated with comorbidities such as developmental deficits and intellectual disability and, in a significant percentage of patients, may be medication‐resistant. The use of adult rodent models in the exploration of mechanisms and treatments for early life epilepsies is challenging, as it ignores significant age‐specific developmental differences. More recently, models developed in immature animals, such as rodent pups, or in three‐dimensional organoids may more closely model aspects of the immature brain and could result in more translatable findings. Although models are not perfect, they may offer a more controlled screening platform in studies of mechanisms and treatments, which cannot be done in pediatric patient cohorts. On the other hand, more simplified models with higher throughput capacities are required to deal with the large number of epilepsy candidate genes and the need for new treatment options. Therefore, a combination of different modeling approaches will be beneficial in addressing the unmet needs of pediatric epilepsy patients. In this review, we summarize the discussions on this topic that occurred during the XVI Workshop on Neurobiology of Epilepsy, organized in 2022 by the Neurobiology Commission of the International League Against Epilepsy. We provide an overview of selected models of early onset epilepsies, discussing their advantages and disadvantages. Heterologous expression models provide initial functional insights, and zebrafish, rodent models, and brain organoids present increasingly complex platforms for modeling and validating epilepsy‐related phenomena. Together, these models offer valuable insights into early onset epilepsies and accelerate hypothesis generation and therapy discovery.


  • Foramen ovale electrode investigation in the era of SEEG: Results and a reappraisal

    by Rohan Jha, Melissa Mj Chua, Noah Nawabi, Sydney S. Cash, John D. Rolston, Andrew J. Cole


  • Open Access

    WONOEP 2022: Neurotechnology for the diagnosis of epilepsy

    by Konrad Wagstyl, Katja Kobow, Pablo M. Casillas‐Espinosa, Andrew J. Cole, Diego Jiménez‐Jiménez, Hiroki Nariai, Stéphanie Baulac, Terence O'Brien, David C. Henshall, Ozlem Akman, et al.

    Epilepsy's myriad causes and clinical presentations ensure that accurate diagnoses and targeted treatments remain a challenge. Advanced neurotechnologies are needed to better characterize individual patients across multiple modalities and analytical techniques. At the XVIth Workshop on Neurobiology of Epilepsy: Early Onset Epilepsies: Neurobiology and Novel Therapeutic Strategies (WONOEP 2022), the session on “advanced tools” highlighted a range of approaches, from molecular phenotyping of genetic epilepsy models and resected tissue samples to imaging‐guided localization of epileptogenic tissue for surgical resection of focal malformations. These tools integrate cutting edge research, clinical data acquisition, and advanced computational methods to leverage the rich information contained within increasingly large datasets. A number of common challenges and opportunities emerged, including the need for multidisciplinary collaboration, multimodal integration, potential ethical challenges, and the multistage path to clinical translation. Despite these challenges, advanced epilepsy neurotechnologies offer the potential to improve our understanding of the underlying causes of epilepsy and our capacity to provide patient‐specific treatment.


  • The complexities underlying epilepsy in people with glioblastoma

    by Elisaveta Sokolov, Jorg Dietrich, Andrew J Cole


  • Interrater Reliability of Expert Electroencephalographers Identifying Seizures and Rhythmic and Periodic Patterns in EEGs

    by Jin Jing, Wendong Ge, Aaron F. Struck, Marta Bento Fernandes, Shenda Hong, Sungtae An, Safoora Fatima, Aline Herlopian, Ioannis Karakis, Jonathan J. Halford, et al.

    Background and Objectives: The validity of brain monitoring using electroencephalography (EEG), particularly to guide care in patients with acute or critical illness, requires that experts can reliably identify seizures and other potentially harmful rhythmic and periodic brain activity, collectively referred to as “ictal-interictal-injury continuum" (IIIC). Prior inter-rater reliability (IRR) studies are limited by small samples and selection bias. This study was conducted to assess the reliability of experts in identifying IIIC. Methods: This prospective analysis included 30 experts with subspecialty clinical neurophysiology training from 18 institutions. Experts independently scored varying numbers of ten-second EEG segments as: “Seizure (SZ)”, “Lateralized Periodic Discharges (LPD)”, “Generalized Periodic Discharges (GPD)”, “Lateralized Rhythmic Delta Activity (LRDA)”, “Generalized Rhythmic Delta Activity (GRDA)”, or “Other”. EEGs were performed for clinical indications at Massachusetts General Hospital between 2006 to 2020. Primary outcome measures were pairwise IRR (average percent agreement (PA) between pairs of experts) and majority IRR (average PA with group consensus) for each class; and beyond chance agreement (κ). Secondary outcomes were calibration of expert scoring to group consensus, and latent trait analysis to investigate contributions of bias and noise to scoring variability. Results: Among 2,711 EEGs, 49% were from females, and median (IQR) age was 55 (41). In total experts scored 50,697 EEG segments; the median [range] number scored by each expert was 6,287.5 [1,002, 45,267]. Overall pairwise IRR was moderate (PA 52%, κ 42%), and majority IRR was substantial (PA 65%, κ 61%). Noise-bias analysis demonstrated that a single underlying receiver operating curve can account for most variation in experts9 false positive vs true positive characteristics (median [range] of variance explained (R2): 95 [93, 98]%), and for most variation in experts’ precision vs sensitivity characteristics (R2: 75 [59, 89]%). Thus, variation between experts is mostly attributable not to differences in expertise, but rather to variation in decision thresholds. Discussion: Our results provide precise estimates of expert reliability from a large and diverse sample, and a parsimonious theory to explain the origin of disagreements between experts. The results also establish a standard for how well an automated IIIC classifier must perform to match experts. Classification of Evidence: This study provides Class II evidence that independent expert review reliably identifies ictal-interictal injury continuum patterns on EEG compared to expert consensus.


  • Focal cortical dysplasia IIb: Near‐continuous rhythmic fast spike burst pattern on intracranial EEG with atypical electroclinical‐clinical semiology

    by Irfan S. Sheikh, Fabio A. Nascimento, Amrit Misra, Melanie Lang‐Orsini, Andrew J. Cole, R. Mark Richardson, Sydney S. Cash

  • Experimental Neurotherapeutics: Surfing the Tidal Wave of New Opportunities

    by Lauren B. Reoma, Ania Busza, M. Maral Mouradian, Petra Kaufmann, Erika F. Augustine, Samuel Frank, Thomas P. Sutula, Andrew J. Cole, Heather D. Fitter, William Meurer, et al.

    The subspecialty of experimental neurotherapeutics trains neurologists in discovering and developing new treatments for neurologic diseases. Based on development of exciting new treatments for genetic and inflammatory diseases, we predict that there will be many other breakthroughs. The job market has expanded rapidly in academia, the pharmaceutical industry, government, and not-for-profit sectors; many new opportunities can be anticipated. The burgeoning opportunities in the field mandate that training address the challenges of overcoming obstacles in therapeutic discovery, implementation science, and development of affordable and equitably available treatments. ANN NEUROL 2023